Per Fischer is the founder of Minervax. Minervax has raised $127M in total funding. Backed by EQT Life Sciences, OrbiMed, Novo Holdings.
Per Fischer is the CEO of MinervaX, a privately held Danish biotechnology company focused on developing a novel, prophylactic vaccine against Group B Streptococcus (GBS). The company recently secured EUR 54 million in an upsized financing round to advance its maternal vaccine towards Phase III clinical trials.
Full founder directory · Investor directory · Company funding database · Fundraising library